三级aa视频在线观看-三级国产-三级国产精品一区二区-三级国产三级在线-三级国产在线

US EUROPE AFRICA ASIA 中文
Business / Companies

Xi'an Janssen plans 10 drug launches in four areas by 2020

By Wang Wen (China Daily) Updated: 2015-10-31 09:50

Xi'an Janssen Pharmaceutical Ltd, Johnson & Johnson Services Inc's largest subsidiary in China, plans to launch more than 10 new medicines in China by 2020.

Kris Sterkens, chairman of Jassen Asia Pacific, said innovation remains its core strategy, and its products will be spread over four main treatment areas: tumors, the autoimmune system, mental health and infectious and metabolic diseases such as hepatitis and diabetes.

The firm's new-product strategy, he said, was being supported by a number of recent findings that showed China has strong demand for medicine targeted at those diseases.

A survey by the Economist Intelligence Unit, a global business intelligence belonging to the Economist Group, for instance, analyzed markets in five countries across Asia Pacific including China, and reached the conclusion that "the region now carries a huge global burden of non-communicable diseases, such as cancer and mental illness".

As many as 85 percent of deaths in China in 2010 were the result of non-communicable diseases, according to the report, with cancer, cardiovascular disease and diabetes topping the list of causes.

"Healthcare systems in Asia Pacific are struggling to manage the rise in non-communicable diseases and the shift to long-term treatment of chronic conditions," said Charles Ross, the survey report's editor.

Following on from those and other findings, Xi'an Janssen will launch a new product for prostate cancer soon, said Sterkens. Research is also being conducted on a diabetes medicine.

Xi'an Janssen has launched 14 major new products in the past five years aimed at treating conditions like human immunodeficiency virus, cancer and mental illness.

Established 30 years ago, it has been a regular investor in China since its launch.

A new $290 million plant in Xi'an will be in operation from 2018, said Cesar Rodriguez, the company's chief.

The new site will have an annual capacity of 280 million medicine packages, which will be sold around the world, said Rodriguez.

Xi'an Janssen is well known in China for over-the-counter drugs such as Domperidone and Daktarin.

Johnson & Johnson combined its OTC business in China last year with Xi'an Janssen, a controversial move at the time with some industry commentators fearing the integration might hurt sales.

Rodriguez insisted the integration, named One China OTC, has achieved strong results, although he refused to detail exact numbers.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 成人国产精品高清在线观看 | 日韩a级片 | 黄频免费影院 | 黄免费观看 | 国产精品成人观看视频国产奇米 | 亚洲婷婷网| 国产视频一二三 | 97视频久久 | 青青操免费在线视频 | 色综合五月婷婷 | www.亚洲一区二区三区 | 欧美成人免费mv在线播放 | 国产精品久久久久免费视频 | 国产免费片 | 国产精品免费看 | 欧美成人一级毛片 | 色婷婷久久 | 麻豆igao在线视频 | 国产一级片免费视频 | 2022国产成人福利精品视频 | 日韩特级毛片 | 国产一区二区三区四区在线观看 | 99视频国产在线 | 九九成人免费视频 | 国产成人在线免费观看 | 青青青草网站免费视频在线观看 | 欧美激情视频一区二区免费 | 国产黄在线观看免费观看软件视频 | 日本视频中文字幕一区二区 | 免费黄色小视频在线观看 | 欧美成人高清乱码 | 久久国产精品久久久久久小说 | 黄色片在线免费观看 | 91青草视频| 日韩激情无码免费毛片 | 免费看欧美毛片大片免费看 | 轻轻啪在线视频播放 | 国产美女在线播放 | 国产亚洲欧美在线 | 一区二区三区免费高清视频 | 一级毛片免费不卡 |